ARGX – argenx SE
ARGX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.37
Margin Of Safety %
-1
Put/Call OI Ratio
0.63
EPS Next Q Diff
0.3
EPS Last/This Y
0.88
EPS This/Next Y
9.31
Price
803.16
Target Price
1044.57
Analyst Recom
1.3
Performance Q
-3.82
Upside
-14.6%
Beta
0.47
Ticker: ARGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-14 | ARGX | 828.91 | 0.60 | 0.43 | 7445 |
| 2026-04-15 | ARGX | 841.54 | 0.60 | 0.61 | 7520 |
| 2026-04-20 | ARGX | 835.22 | 0.52 | 2.53 | 6013 |
| 2026-04-23 | ARGX | 788.21 | 0.53 | 1.29 | 6163 |
| 2026-04-24 | ARGX | 781.03 | 0.54 | 10.44 | 6187 |
| 2026-04-27 | ARGX | 783.94 | 0.59 | 0.33 | 6391 |
| 2026-04-28 | ARGX | 775.44 | 0.59 | 0.05 | 6407 |
| 2026-04-29 | ARGX | 775.9 | 0.58 | 1.27 | 6463 |
| 2026-04-30 | ARGX | 781.76 | 0.58 | 0.71 | 6475 |
| 2026-05-01 | ARGX | 783.62 | 0.58 | 0.28 | 6491 |
| 2026-05-04 | ARGX | 811.05 | 0.58 | 1.22 | 6503 |
| 2026-05-05 | ARGX | 794.88 | 0.59 | 0.14 | 6622 |
| 2026-05-06 | ARGX | 804.26 | 0.58 | 0.57 | 6727 |
| 2026-05-07 | ARGX | 787.17 | 0.58 | 0.14 | 7214 |
| 2026-05-08 | ARGX | 782.18 | 0.58 | 3.33 | 7242 |
| 2026-05-11 | ARGX | 813.47 | 0.65 | 0.06 | 7683 |
| 2026-05-12 | ARGX | 813.54 | 0.63 | 0.71 | 7370 |
| 2026-05-13 | ARGX | 803.16 | 0.63 | 0.16 | 7370 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-14 | ARGX | 828.53 | 89.6 | 753.2 | 21.51 |
| 2026-04-15 | ARGX | 840.94 | 89.6 | 690.1 | 21.51 |
| 2026-04-16 | ARGX | 828.87 | 88.9 | 642.0 | 21.50 |
| 2026-04-17 | ARGX | 849.60 | 88.9 | 733.6 | 21.50 |
| 2026-04-20 | ARGX | 834.59 | 88.5 | 707.1 | 21.43 |
| 2026-04-21 | ARGX | 805.40 | 88.5 | 624.3 | 21.43 |
| 2026-04-22 | ARGX | 793.70 | 88.5 | 654.0 | 21.43 |
| 2026-04-23 | ARGX | 787.97 | 88.5 | 681.3 | 21.43 |
| 2026-04-24 | ARGX | 780.93 | 88.5 | 639.9 | 21.43 |
| 2026-04-27 | ARGX | 784.70 | 88.5 | 710.8 | 21.43 |
| 2026-04-28 | ARGX | 774.68 | 84.5 | 646.3 | 21.46 |
| 2026-04-30 | ARGX | 781.24 | 84.5 | 730.3 | 21.46 |
| 2026-05-01 | ARGX | 783.89 | 84.5 | 696.0 | 21.46 |
| 2026-05-04 | ARGX | 810.54 | 84.5 | 761.5 | 21.47 |
| 2026-05-05 | ARGX | 794.71 | 84.5 | 664.0 | 21.47 |
| 2026-05-06 | ARGX | 806.62 | 84.5 | 740.4 | 21.47 |
| 2026-05-07 | ARGX | 787.30 | 84.5 | 604.5 | 21.47 |
| 2026-05-08 | ARGX | 782.50 | 47.6 | 662.4 | 21.47 |
| 2026-05-11 | ARGX | 813.30 | 47.6 | 528.7 | 21.47 |
| 2026-05-12 | ARGX | 813.24 | 59.9 | 461.5 | 22.09 |
| 2026-05-13 | ARGX | 803.16 | 59.9 | 477.2 | 21.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-14 | ARGX | 0.00 | -2.48 | 3.61 |
| 2026-04-15 | ARGX | 0.00 | -2.48 | 3.61 |
| 2026-04-16 | ARGX | 0.00 | -2.48 | 3.61 |
| 2026-04-17 | ARGX | 0.00 | -2.48 | 3.61 |
| 2026-04-20 | ARGX | 0.00 | -2.43 | 3.61 |
| 2026-04-21 | ARGX | 0.00 | -2.43 | 3.61 |
| 2026-04-22 | ARGX | 0.00 | -2.43 | 3.61 |
| 2026-04-23 | ARGX | 0.00 | -2.43 | 3.61 |
| 2026-04-24 | ARGX | 0.00 | -2.43 | 3.61 |
| 2026-04-27 | ARGX | 0.00 | -2.56 | 3.70 |
| 2026-04-28 | ARGX | 0.00 | -2.56 | 3.70 |
| 2026-04-29 | ARGX | 0.00 | -2.56 | 3.70 |
| 2026-04-30 | ARGX | 0.00 | -2.56 | 3.70 |
| 2026-05-01 | ARGX | 0.00 | -2.56 | 3.70 |
| 2026-05-04 | ARGX | 0.00 | -2.57 | 3.70 |
| 2026-05-05 | ARGX | 0.00 | -2.57 | 3.70 |
| 2026-05-06 | ARGX | 0.00 | -2.57 | 3.70 |
| 2026-05-07 | ARGX | 0.00 | -2.57 | 3.70 |
| 2026-05-08 | ARGX | 0.00 | -2.57 | 3.70 |
| 2026-05-11 | ARGX | 0.00 | -2.83 | 3.70 |
| 2026-05-12 | ARGX | 0.00 | -2.83 | 3.37 |
| 2026-05-13 | ARGX | 0.00 | -2.83 | 3.37 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.52
Avg. EPS Est. Current Quarter
5.21
Avg. EPS Est. Next Quarter
5.82
Insider Transactions
Institutional Transactions
-2.83
Beta
0.47
Average Sales Estimate Current Quarter
1225
Average Sales Estimate Next Quarter
1324
Fair Value
791.25
Quality Score
94
Growth Score
84
Sentiment Score
74
Actual DrawDown %
14.1
Max Drawdown 5-Year %
-38.2
Target Price
1044.57
P/E
40.99
Forward P/E
22.03
PEG
0.67
P/S
11.94
P/B
6.78
P/Free Cash Flow
59.17
EPS
19.58
Average EPS Est. Cur. Y
21.96
EPS Next Y. (Est.)
31.27
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
31.09
Relative Volume
1.12
Return on Equity vs Sector %
-6.5
Return on Equity vs Industry %
9
EPS 1 7Days Diff
0.5
EPS 1 30Days Diff
0.46
EBIT Estimation
477.2
◆
ARGX
Healthcare
$802.70
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
54
Range 1M
45.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
37.3%
EPS NY
35.6%
52W%
68%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+23.7% upside
Upside
+23.7%
Quality
94
MoS
-1%
argenx SESector: Healthcare
Industry: Biotechnology
Employees: 1863
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX
Latest News
—
Caricamento notizie per ARGX…
stock quote shares ARGX – argenx SE Stock Price stock today
news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025
marketwatch ARGX – argenx SE yahoo finance google finance
stock history ARGX – argenx SE invest stock market
stock prices ARGX premarket after hours
ticker ARGX fair value insiders trading